Development and Evaluation of Indole-Based Phospholipase D Inhibitors for Lung Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• Lung cancer is a leading cause of cancer mortality worldwide, necessitating novel therapeutic strategies.
• Phospholipase D (PLD) is implicated in cancer progression and immune evasion, making it a potential therapeutic target.
• Developing effective PLD inhibitors is crucial for advancing cancer treatment.

Purpose of the Study:

• To synthesize and evaluate novel indole-based phospholipase D (PLD) inhibitors for anticancer efficacy, particularly in lung cancer.
• To elucidate the mechanism of action of these inhibitors, including their binding to PLD1 and modulation of oncogenic pathways.
• To assess the therapeutic potential of PLD inhibitors, alone and in combination with chemotherapy, in preclinical models.

Main Methods:

• Synthesis of indole-based compounds and structure-activity relationship (SAR) studies to identify potent PLD inhibitors.
• In vitro assays to assess inhibition of cell growth, viability, migration, and induction of apoptosis in lung cancer cells.
• In silico molecular docking to confirm binding interactions with the PLD1 active site.
• In vivo studies in mouse models to evaluate tumor reduction and immune response modulation.
• Combination studies with gemcitabine to assess synergistic effects.

Main Results:

• A key indole-based compound was identified that potently inhibits PLD, suppressing lung cancer cell proliferation, viability, and migration.
• In silico analysis confirmed the inhibitor's binding to the PLD1 active site, elucidating key interactions.
• The inhibitor modulated oncogenic pathways and immune evasion mechanisms in lung cancer cells.
• In vivo studies demonstrated tumor growth inhibition and altered immune responses.
• Combination therapy with gemcitabine showed synergistic enhancement of anti-cancer effects.

Conclusions:

• Indole-based PLD inhibitors represent a promising new class of therapeutics for lung cancer.
• These inhibitors demonstrate potent anticancer activity through direct cytotoxicity and immunomodulation.
• Combination strategies involving PLD inhibitors may enhance treatment efficacy and overcome resistance.